Fulcrum Therapeutics Inc Forecast, price target & analysts
Fulcrum Therapeutics Inc Target price 2024 - Analyst rating & recommendation
Fulcrum Therapeutics Inc Classifications & Recommendation:
Fulcrum Therapeutics Inc Price Target
| Target Price | $5.29 |
| Price | $3.44 |
| Potential |
53.65%
register free of charge
|
| Number of Estimates | 7 |
|
7 Analysts have issued a price target Fulcrum Therapeutics Inc 2025 .
The average Fulcrum Therapeutics Inc target price is $5.29.
This is
53.65%
register free of charge
$14.00
306.98%
register free of charge
$2.00
41.86%
register free of charge
|
|
| A rating was issued by 8 analysts: 2 Analysts recommend Fulcrum Therapeutics Inc to buy, 5 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Fulcrum Therapeutics Inc stock has an average upside potential 2025 of
53.65%
register free of charge
|
Sales and Margin forecast 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Revenue Million $ | 2.81 | 80.35 |
| 55.68% | 2,759.58% | |
| EBITDA Margin | -3,860.85% | -24.53% |
| 123.09% | 99.36% | |
| Net Margin | -3,052.12% | -5.37% |
| 47.02% | 99.82% |
8 Analysts have issued a sales forecast Fulcrum Therapeutics Inc 2024 . The average Fulcrum Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
2 Analysts have issued an Fulcrum Therapeutics Inc EBITDA forecast 2024. The average Fulcrum Therapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Margin
| 2023 | -3,860.85% | 123.09% |
|---|---|---|
| 2024 |
-24.53%
99.36%
Unlock
|
|
1 Analyst has issued a net profit forecast Fulcrum Therapeutics Inc 2024 . The average Fulcrum Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Net Margin
| 2023 | -3,052.12% | 47.02% |
|---|---|---|
| 2024 |
-5.37%
99.82%
Unlock
|
|
Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.59 | -0.08 |
| 34.84% | 94.97% | |
| P/E | negative | |
| EV/Sales | negative |
1 Analysts have issued a Fulcrum Therapeutics Inc forecast for earnings per share. The average Fulcrum Therapeutics Inc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Fulcrum Therapeutics Inc stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Fulcrum Therapeutics Inc...
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
